2004
DOI: 10.1111/j.1464-5491.2004.01207.x
|View full text |Cite
|
Sign up to set email alerts
|

Improving glycaemic control of patients with Type 2 diabetes in a primary care setting: a French application of the Staged Diabetes Management programme

Abstract: Educating GPs in the French adaptation of the SDM programme improves glycaemic control in a primary care setting, without significantly increasing healthcare costs.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
55
1

Year Published

2005
2005
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 34 publications
(58 citation statements)
references
References 22 publications
2
55
1
Order By: Relevance
“…In the French study, no improvement in blood pressure or lipid profile was seen [13]. In our study, the reduction in the mean systolic and diastolic blood pressures in the intervention group was bigger than in a Danish trial of structured care [21].…”
Section: Discussioncontrasting
confidence: 51%
See 3 more Smart Citations
“…In the French study, no improvement in blood pressure or lipid profile was seen [13]. In our study, the reduction in the mean systolic and diastolic blood pressures in the intervention group was bigger than in a Danish trial of structured care [21].…”
Section: Discussioncontrasting
confidence: 51%
“…In the intervention group, there was a reduction of 1.6% in HbA 1c compared with 0.4% in the control group. In a French study exploring training with SDM in primary care, the HbA 1c was 0.87% lower in the intervention than in the control group after 12 months [13]. Benjamin et al reported a 0.9% reduction in HbA 1c at 15 months with SDM-implemented protocols in primary care provided by an academic centre [18].…”
Section: Discussionmentioning
confidence: 97%
See 2 more Smart Citations
“…21,22,23,24 All study centers agreed to establish short-and long-term treatment goals for blood glucose management (HbA 1c Ͻ 7%), blood pressure control (blood pressure [BP] Ͻ 130/80 mmHg), and lipid abnormalities (low-density lipoprotein [LDL] cholesterol Ͻ 100). Changes in regimen were indicated if the patient was not at target levels within 3 months of initiating treatment or if there was no improvement.…”
Section: Phasementioning
confidence: 99%